Unauthorized Use of Content on this Site: The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB)—including, but not limited to, those available through the PAAB Forum, the PAAB website, and any PAAB correspondence—are specifically intended to assist individuals navigating the PAAB preclearance system. Repurposing or reproducing this content, or using it for model training or any related purposes, is strictly prohibited without the express prior written consent of PAAB. This includes, but is not limited to, the use of such materials in automated systems, machine learning models, or artificial intelligence applications.
APS discussing diagnostic test
-
Hello PAAB,
If a diagnostic test is required to determine eligibility for a drug, and we create a leave behind for HCPs explaining what the test is, how to order it, information on testing centres etc
- Either without mentioning the drug name at all, and not having any branding elements tying to the drug
- Or mentioning the drug name in a non-promotional, informational sense, also sans branding elements
Would such a piece be PAAB-exempt in one or both scenarios? Thanks for your guidance!
-
Good morning @supraja
An unbranded leave behind outlining a diagnostic test that is not exclusive to drug treatment and is part of the natural course of diagnosis and is being used as a standalone piece, may be considered exempt if it is limited to diagnosis (i.e. does not make mention of treatment or suggest treatment as a result of the test). Detailing/distributing this piece with branded content would render it subject to review (linkage principles). In the context of a branded piece and/or “mentioning a drug name in a non-promotional” context, the piece would not be exempt.
-
@jennifer-carroll Thanks very much, this is helpful!
